Skip to Content
Merck
All Photos(2)

Key Documents

View All Documentation

GF13609111

Lanthanum

foil, 25x25mm, thickness 0.125mm, as rolled, 99%

Synonym(s):

Lanthanum, LA000215

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
La
CAS Number:
7439-91-0
Molecular Weight:
138.91
MDL number:
MFCD00011066
UNSPSC Code:
12141607
PubChem Substance ID:
329802134
NACRES:
NA.23

Assay

99%

form

foil

manufacturer/tradename

Goodfellow 136-091-11

resistivity

54 μΩ-cm

size × thickness

25 x 25 mm × 0.125 mm

bp

3464 °C (lit.)

mp

920 °C (lit.)

density

6.19 g/mL at 25 °C (lit.)

SMILES string

[La]

InChI

1S/La

InChI key

FZLIPJUXYLNCLC-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

For updated SDS information please visit www.goodfellow.com.

Legal Information

Product of Goodfellow

Storage Class Code

4.3 - Hazardous materials which set free flammable gases upon contact with water

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Stuart M Sprague
Current medical research and opinion, 23(12), 3167-3175 (2007-11-10)
Obstacles to successful management of hyperphosphatemia in chronic kidney disease include inadequate control of dietary phosphate and non-compliance with phosphate-binder therapy. Three major classes of phosphate binders include calcium-based binders, sevelamer HCl, and lanthanum carbonate. A literature search was performed
Declan de Freitas et al.
Seminars in dialysis, 20(4), 325-328 (2007-07-20)
Hyperphosphatemia is associated with increased morbidity and mortality in dialysis patients. Oral phosphate binders are necessary to control serum phosphate in patients eating a normal diet and undergoing peritoneal dialysis or thrice weekly hemodialysis. Until recently, none of the available
Amy Barton Pai et al.
Expert opinion on drug metabolism & toxicology, 5(1), 71-81 (2009-02-25)
Hyperphosphatemia is recognized as a principal mineral disorder in chronic kidney disease (CKD) that leads to the development of secondary hyperparathyroidism. Recent data indicate that hyperphosphatemia is associated with accelerated cardiac calcification and increased mortality in patients with CKD. Control
Stephen J P Damment et al.
Clinical pharmacokinetics, 47(9), 553-563 (2008-08-14)
Lanthanum carbonate is considered to be the most potent of a new generation of noncalcium phosphate binders used to treat hyperphosphataemia in chronic kidney disease (CKD), a condition associated with progressive bone and cardiovascular pathology and a markedly elevated risk
Gadolinium and lanthanum: a iatrogenic transmetallation?
Simona Brambilla et al.
Clinical biochemistry, 41(13), 1029-1033 (2008-06-19)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service